- Home
- NHS vs AMRN Comparison
NHS vs AMRN Comparison
Compare NHS & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- AMRN
- Stock Information
- Founded
- NHS 2003
- AMRN 1989
- Country
- NHS United States
- AMRN Ireland
- Employees
- NHS N/A
- AMRN N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- NHS Finance
- AMRN Health Care
- Exchange
- NHS Nasdaq
- AMRN Nasdaq
- Market Cap
- NHS 221.6M
- AMRN 216.0M
- IPO Year
- NHS N/A
- AMRN 1993
- Fundamental
- Price
- NHS $7.50
- AMRN $16.19
- Analyst Decision
- NHS
- AMRN Strong Sell
- Analyst Count
- NHS 0
- AMRN 1
- Target Price
- NHS N/A
- AMRN $12.00
- AVG Volume (30 Days)
- NHS 111.8K
- AMRN 166.2K
- Earning Date
- NHS 01-01-0001
- AMRN 07-30-2025
- Dividend Yield
- NHS 13.44%
- AMRN N/A
- EPS Growth
- NHS N/A
- AMRN N/A
- EPS
- NHS N/A
- AMRN N/A
- Revenue
- NHS N/A
- AMRN $214,112,000.00
- Revenue This Year
- NHS N/A
- AMRN N/A
- Revenue Next Year
- NHS N/A
- AMRN $7.88
- P/E Ratio
- NHS N/A
- AMRN N/A
- Revenue Growth
- NHS N/A
- AMRN N/A
- 52 Week Low
- NHS $6.95
- AMRN $7.08
- 52 Week High
- NHS $9.17
- AMRN $17.18
- Technical
- Relative Strength Index (RSI)
- NHS 47.33
- AMRN 76.95
- Support Level
- NHS $7.37
- AMRN $12.30
- Resistance Level
- NHS $7.60
- AMRN $17.18
- Average True Range (ATR)
- NHS 0.07
- AMRN 1.10
- MACD
- NHS -0.02
- AMRN 0.24
- Stochastic Oscillator
- NHS 38.24
- AMRN 82.10
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.